FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189742732> ?p ?o ?g. }

• W3189742732 abstract "Anti-diabetic biguanide drugs such as metformin may have anti-tumorigenic effects by behaving as AMPK activators and mTOR inhibitors. Metformin requires organic cation transporters (OCTs) for entry into cells, and NT-1044 is an AMPK activator designed to have greater affinity for two of these transporters, OCT1 and OCT3. We sought to compare the effects of NT-1044 on cell proliferation in human endometrial cancer (EC) cell lines and on tumor growth in an endometrioid EC mouse model.Cell proliferation was assessed in two EC cell lines, ECC-1 and Ishikawa, by MTT assay after exposure to NT-1044 for 72 hours of treatment. Apoptosis was analyzed by Annexin V-FITC and cleaved caspase 3 assays. Cell cycle progression was evaluated by Cellometer. Reactive oxygen species (ROS) were measured using DCFH-DA and JC-1 assays. For the in vivo studies, we utilized the LKB1fl/flp53fl/fl mouse model of endometrioid endometrial cancer. The mice were treated with placebo or NT-1044 or metformin following tumor onset for 4 weeks.NT-1044 and metformin significantly inhibited cell proliferation in a dose-dependent manner in both EC cell lines after 72 hours of exposure (IC50 218 μM for Ishikawa; 87 μM for ECC-1 cells). Treatment with NT-1044 resulted in G1 cell cycle arrest, induced apoptosis and increased ROS production in both cell lines. NT-1044 increased phosphorylation of AMPK and decreased phosphorylation of S6, a key downstream target of the mTOR pathway. Expression of the cell cycle proteins CDK4, CDK6 and cyclin D1 decreased in a dose-dependent fashion while cellular stress protein expression was induced in both cell lines. As compared to placebo, NT-1044 and metformin inhibited endometrial tumor growth in obese and lean LKB1fl/flp53fl/fl mice.NT-1044 suppressed EC cell growth through G1 cell cycle arrest, induction of apoptosis and cellular stress, activation of AMPK and inhibition of the mTOR pathway. In addition, NT-1044 inhibited EC tumor growth in vivo under obese and lean conditions. More work is needed to determine if this novel biguanide will be beneficial in the treatment of women with EC, a disease strongly impacted by obesity and diabetes." @default.
• W3189742732 created "2021-08-16" @default.
• W3189742732 creator A5001103132 @default.
• W3189742732 creator A5007925500 @default.
• W3189742732 creator A5012002580 @default.
• W3189742732 creator A5038121350 @default.
• W3189742732 creator A5044757881 @default.
• W3189742732 creator A5058573976 @default.
• W3189742732 creator A5068522544 @default.
• W3189742732 creator A5074712841 @default.
• W3189742732 creator A5080806609 @default.
• W3189742732 creator A5084844090 @default.
• W3189742732 date "2021-08-05" @default.
• W3189742732 modified "2023-10-15" @default.
• W3189742732 title "The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and In Vivo Tumor Growth" @default.
• W3189742732 cites W1786380341 @default.
• W3189742732 cites W1969542174 @default.
• W3189742732 cites W1971931804 @default.
• W3189742732 cites W1979652171 @default.
• W3189742732 cites W1980359753 @default.
• W3189742732 cites W1982807885 @default.
• W3189742732 cites W1985139403 @default.
• W3189742732 cites W1987157665 @default.
• W3189742732 cites W1988609792 @default.
• W3189742732 cites W1994163115 @default.
• W3189742732 cites W2001568034 @default.
• W3189742732 cites W2004516503 @default.
• W3189742732 cites W2019017315 @default.
• W3189742732 cites W2020474316 @default.
• W3189742732 cites W2026967508 @default.
• W3189742732 cites W2040608814 @default.
• W3189742732 cites W2041440766 @default.
• W3189742732 cites W2042648780 @default.
• W3189742732 cites W2045448921 @default.
• W3189742732 cites W2059367589 @default.
• W3189742732 cites W2063507291 @default.
• W3189742732 cites W2066032552 @default.
• W3189742732 cites W2072900847 @default.
• W3189742732 cites W2078224872 @default.
• W3189742732 cites W2084108624 @default.
• W3189742732 cites W2085331940 @default.
• W3189742732 cites W2088122814 @default.
• W3189742732 cites W2091296592 @default.
• W3189742732 cites W2098733239 @default.
• W3189742732 cites W2102648794 @default.
• W3189742732 cites W2123014930 @default.
• W3189742732 cites W2131180390 @default.
• W3189742732 cites W2141662760 @default.
• W3189742732 cites W2147284001 @default.
• W3189742732 cites W2147589302 @default.
• W3189742732 cites W2147990180 @default.
• W3189742732 cites W2148842373 @default.
• W3189742732 cites W2150876331 @default.
• W3189742732 cites W2161640106 @default.
• W3189742732 cites W2167264978 @default.
• W3189742732 cites W2336831152 @default.
• W3189742732 cites W2419098006 @default.
• W3189742732 cites W2761870610 @default.
• W3189742732 cites W2776639172 @default.
• W3189742732 cites W2805627963 @default.
• W3189742732 cites W2900647301 @default.
• W3189742732 cites W2924457271 @default.
• W3189742732 cites W2959651197 @default.
• W3189742732 cites W2984093425 @default.
• W3189742732 cites W3014080938 @default.
• W3189742732 cites W3020015603 @default.
• W3189742732 cites W3097178624 @default.
• W3189742732 cites W3119005666 @default.
• W3189742732 cites W3124511465 @default.
• W3189742732 cites W4241479729 @default.
• W3189742732 cites W4296146232 @default.
• W3189742732 doi "https://doi.org/10.3389/fonc.2021.690435" @default.
• W3189742732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8377676" @default.
• W3189742732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34422646" @default.
• W3189742732 hasPublicationYear "2021" @default.
• W3189742732 type Work @default.
• W3189742732 sameAs 3189742732 @default.
• W3189742732 citedByCount "5" @default.
• W3189742732 countsByYear W31897427322022 @default.
• W3189742732 countsByYear W31897427322023 @default.
• W3189742732 crossrefType "journal-article" @default.
• W3189742732 hasAuthorship W3189742732A5001103132 @default.
• W3189742732 hasAuthorship W3189742732A5007925500 @default.
• W3189742732 hasAuthorship W3189742732A5012002580 @default.
• W3189742732 hasAuthorship W3189742732A5038121350 @default.
• W3189742732 hasAuthorship W3189742732A5044757881 @default.
• W3189742732 hasAuthorship W3189742732A5058573976 @default.
• W3189742732 hasAuthorship W3189742732A5068522544 @default.
• W3189742732 hasAuthorship W3189742732A5074712841 @default.
• W3189742732 hasAuthorship W3189742732A5080806609 @default.
• W3189742732 hasAuthorship W3189742732A5084844090 @default.
• W3189742732 hasBestOaLocation W31897427321 @default.
• W3189742732 hasConcept C11960822 @default.
• W3189742732 hasConcept C134018914 @default.
• W3189742732 hasConcept C185592680 @default.
• W3189742732 hasConcept C190283241 @default.
• W3189742732 hasConcept C2780124434 @default.
• W3189742732 hasConcept C2780323712 @default.
• W3189742732 hasConcept C29537977 @default.
• W3189742732 hasConcept C502942594 @default.

• next